Marshall Wace’s Structure Therapeutics GPCR Stock Holding History

Marshall Wace’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.4M	Buy	267,592 +198,485	+287%	+$8.78M	0.01%	876
2026 Q1	$3.33M	Sell	69,107 -99,477	-59%	-$6.81M	﹤0.01%	1516
2025 Q4	$11.7M	Buy	+168,584	New	+$6.88M	0.01%	815
2025 Q3	–	Sell	-176,060	Closed	-$3.65M	–	3071
2025 Q2	$3.65M	Buy	176,060 +145,434	+475%	+$3.2M	﹤0.01%	1299
2025 Q1	$530K	Sell	30,626 -552,581	-95%	-$13.5M	﹤0.01%	2057
2024 Q4	$15.8M	Buy	583,207 +450,531	+340%	+$16M	0.02%	619
2024 Q3	$5.82M	Buy	132,676 +56,742	+75%	+$2.19M	0.01%	938
2024 Q2	$2.98M	Buy	75,934 +40,693	+115%	+$1.67M	﹤0.01%	1199
2024 Q1	$1.51M	Sell	35,241 -70,529	-67%	-$2.97M	﹤0.01%	1490
2023 Q4	$4.31M	Sell	105,770 -1,748	-2%	-$100K	0.01%	960
2023 Q3	$5.42M	Buy	+107,518	New	+$3.46M	0.01%	844

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace's GPCR Position: Q2 2026 in Review

Marshall Wace increased its Structure Therapeutics (GPCR) stake by 287% in Q2 2026, buying an estimated $8.78M and bringing the position to 267,592 shares worth $14.4M. The position accounts for 0.01% of the portfolio, ranked #876.

Marshall Wace first reported a position in GPCR in Q3 2023 and has held it in 11 quarters since. The position peaked at $15.8M in Q4 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Marshall Wace held 267,592 shares of Structure Therapeutics worth $14.4M as of Q2 2026.
Marshall Wace bought 198,485 Structure Therapeutics shares in Q2 2026, an estimated $8.78M.
Structure Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #876 holding.
Marshall Wace first reported a position in Structure Therapeutics in Q3 2023 and has held it in 11 quarters since.
Marshall Wace's Structure Therapeutics position peaked at $15.8M in Q4 2024.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.